Media Center

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

  • French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
  • Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
  • Allergic rhinitis affects up to 25% of the population of Western Europe annually

Levallois-Perret, June 2, 2014: Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, the first generic version of leading respiratory therapy Nasonex®1. Mometasone Sandoz® is indicated for the treatment of conditions including allergic rhinitis.

"Sandoz France is proud to announce the market introduction of the first ever specialty generic medicine indicated for the treatment of a respiratory condition in combination with an inhaler device", said Frédéric Collet, President of Sandoz France.

Jan-Torsten Tews, Head of Global Respiratory for Sandoz, said: “Allergic rhinitis is a common condition that has become increasingly prevalent over the past decade, which significantly affects the quality of life of those affected. We are pleased to offer patients and payors in France, one of our main global markets, a new, affordable and high-quality therapeutic option.”

Allergic rhinitis, an inflammation of the inside of the nose caused by allergens including pollen and dust, affects between 10 and 25 percent of the population in Western Europe on an annual basis2.

Sandoz, one of the two leading generics companies worldwide, aspires to increase access to affordable, high-quality medicines across Europe and worldwide. Respiratory generics represent a key pillar of its strategic focus on complex, differentiated generics and biosimilars, in which it holds leading positions worldwide (including #1 positions in biosimilars, generic injectables, dermatology and ophthalmology).

Sandoz has already launched generic mometasone in countries across Europe, including Austria, Denmark, Finland, Germany, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the UK, and several markets in Central and Eastern Europe.

References

1Nasonex® is a registered trademark of Merck.

2The Journal of Allergy and Clinical Immunology.

About Mometasone Sandoz®

Mometasone Sandoz® 50 micrograms/dose, a nasal spray suspension, is indicated for use (in France) in adults and children over the age of six, to treat symptoms of seasonal allergic rhinitis or perennial allergic rhinitis.

For patients with precursors of moderate to serve symptoms of seasonal allergic rhinitis, preventive treatment with Mometasone Sandoz®, 50 micrograms/dose, may be initiated up to four week before the provisional start of the pollen season. Mometasone Sandoz®, 50 micrograms/dose is also indicated for the symptomatic treatment of nasal polyposis syndrome in adults over the age of 18.

Mometasone Sandoz® 50 micrograms/dose has been approved in France as a generic version of Nasonex® 50 micrograms/dose nasal suspension spray, as of April 8, 2014 (decision of ANSM, pending publication in the Journal Officiel).

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).

For further information, contact:

Frédérique Mathieu-Ordinaire
Sandoz Communications, France
Tel: +33 1 4964 57824
frederique.ordinaire@sandoz.com

Sandoz Global Communications:
Chris Lewis
+49 8024 476 1906
chris.lewis@sandoz.com